New medicines for neurological disease.

Pace Pharmaceuticals is a new kind of drug company. We deeply integrate AI and robotics at all stages, enabling us to develop drugs with unprecedented efficiency.

Explore our compounds →

Generate

AI generates and scores analogs around a promising scaffold.

Design

AI designs the assay to test the top candidates.

Test

AI programs liquid-handling robots to run the plates, around the clock.

Analyze

AI analyzes the data and flags the hits.

Iterate

The process is repeated for many different scaffolds.

PAC-832

A selective small-molecule GalR1 antagonist for Alzheimer’s disease.

Receptor selectivity
PAC-832 concentration-response data showing dose-dependent GalR1 inhibition and no detectable GalR2 or GalR3 response up to 10 micromolar

GalR1–3 concentration response

Recognition memory
Novel object discrimination index by treatment group, showing recovery after PAC-832 at 10 and 30 milligrams per kilogram

Novel object discrimination · N = 25

Behavioral recordings

Vehicle
Novel object Familiar object
PAC-832 · 30 mg/kg
Novel object Familiar object